Daejeon, South Korea

In Seok Hong

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Daejeon, KR (2014)
  • Yongin-si, KR (2016)

Company Filing History:


Years Active: 2014-2016

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: In Seok Hong: Innovator in Cancer Treatment

Introduction

In Seok Hong is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of cancer treatment through his innovative research and development. With a total of 3 patents, his work focuses on the creation of pharmaceutical compositions that aim to improve cancer therapies.

Latest Patents

Among his latest patents, In Seok Hong has developed benzothiazole derivatives that are utilized for the treatment of cancer. These patents include a compound represented by Formula I, along with its pharmaceutically acceptable salts and solvates. The pharmaceutical compositions he has created are designed for both cancer treatment and as radiation sensitizers, enhancing the effectiveness of existing therapies.

Career Highlights

In Seok Hong has worked with esteemed institutions such as the Korea Institute of Radiological & Medical Sciences and the Kongju National University Industry-University Cooperation Foundation. His experience in these organizations has allowed him to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Sung H Hong and Kee Ho Lee. Their collaborative efforts have further advanced the research and development of innovative cancer treatments.

Conclusion

In Seok Hong's contributions to cancer treatment through his patented innovations highlight his dedication to improving healthcare. His work continues to inspire advancements in the medical field, showcasing the importance of innovation in addressing critical health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…